Literature DB >> 14519420

Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum.

Juliana S Baracat1, Cleber E Teixeira, Cristina E Okuyama, Fernanda B M Priviero, Renato Faro, Edson Antunes, Gilberto De Nucci.   

Abstract

5-Cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-4-ylamine (BAY 41-2272) is a potent soluble guanylyl cyclase stimulator in a nitric oxide (NO)-independent manner. The relaxant effect of BAY 41-2272 was investigated in rabbit and human corpus cavernosum in vitro. BAY 41-2272 (0.01-10 microM) relaxed both rabbit (pEC(50)=6.82+/-0.06) and human (pEC(50)=6.12+/-0.10) precontracted cavernosal strips. The guanylyl cyclase inhibitor (ODQ, 10 microM) caused significant rightward shifts in the concentration-response curves for BAY 41-2272 in rabbit (4.7-fold) and human (2.3-fold) tissues. The NO synthesis inhibitor (N-nitro-L-arginine methyl ester (L-NAME), 100 microM) also produced similar rightward shifts, revealing that BAY 41-2272 acts synergistically with endogenous NO to elicit its relaxant effect. The results also indicate that ODQ is selective for the NO-stimulated enzyme, since relaxations evoked by BAY 41-2272 were only partly attenuated by ODQ. The present study shows that both BAY 41-2272 and sildenafil evoke relaxations independent of inhibition of haem in soluble guanylate cyclase. Moreover, there is no synergistic effect of the two compounds in corpus cavernosum.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14519420     DOI: 10.1016/j.ejphar.2003.08.012

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.

Authors:  Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

Review 2.  New insight into the functioning of nitric oxide-receptive guanylyl cyclase: physiological and pharmacological implications.

Authors:  John Garthwaite
Journal:  Mol Cell Biochem       Date:  2009-12-11       Impact factor: 3.396

Review 3.  Stimulators and activators of soluble guanylate cyclase for urogenital disorders.

Authors:  Fabiola Z Mónica; Edson Antunes
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

4.  Relaxant effect of a metal-based drug in human corpora cavernosa and its mechanism of action.

Authors:  A S Leitão Junior; R M Campos; J B G Cerqueira; M C Fonteles; C F Santos; G de Nucci; E H S Sousa; L G F Lopes; L F Gonzaga-Silva; N R F Nascimento
Journal:  Int J Impot Res       Date:  2015-10-29       Impact factor: 2.896

Review 5.  Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.

Authors:  Fernanda B M Priviero; R Clinton Webb
Journal:  J Cardiovasc Pharmacol       Date:  2010-09       Impact factor: 3.105

6.  A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.

Authors:  George F Lasker; Jason H Maley; Philip J Kadowitz
Journal:  Adv Pharmacol Sci       Date:  2010

Review 7.  Looking to the future for erectile dysfunction therapies.

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Oxidative stress impairs vasorelaxation induced by the soluble guanylyl cyclase activator BAY 41-2272 in spontaneously hypertensive rats.

Authors:  Fernanda B M Priviero; Saiprasad M Zemse; Cleber E Teixeira; R Clinton Webb
Journal:  Am J Hypertens       Date:  2009-02-26       Impact factor: 2.689

Review 9.  Gas what: NO is not the only answer to sexual function.

Authors:  G Yetik-Anacak; R Sorrentino; A E Linder; N Murat
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

10.  Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.

Authors:  Camila B Mendes-Silverio; Luiz O S Leiria; Rafael P Morganti; Gabriel F Anhê; Sisi Marcondes; Fabíola Z Mónica; Gilberto De Nucci; Edson Antunes
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.